Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax in Combination With Other Agents in Pediatric R/R AML and B-cell ALL
NCT07770698Phase 2Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2026
- Primary completion
- Apr 2030
01
Overview
A Phase 2 trial of sonrotoclax in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by BeOne Medicines. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07770698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770698.